Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

June 03, 2015 7:52 PM ET


Company Overview of OncoMed Pharmaceuticals, Inc.

Company Overview

OncoMed Pharmaceuticals, Inc., a clinical development-stage biotechnology company, discovers and develops protein therapeutics targeting cancer stem cells (CSCs). Its product candidates target CSCs by blocking self-renewal and driving differentiation of CSCs toward a non-tumorigenic state, as well as impact bulk tumor cells. The company’s product candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), a humanized monoclonal antibody that is in two Phase II clinical trials and one Phase Ib/II clinical trial for the treatment of patients with non-small-cell lung cancer and pancreatic cancer; Anti-DLL4/Anti-vascular endothelial growth factor (VEGF) Bispecific, which has c...

800 Chesapeake Drive

Redwood City, CA 94063

United States

Founded in 2004

108 Employees





Key Executives for OncoMed Pharmaceuticals, Inc.

Chairman, Chief Executive Officer and President
Age: 54
Total Annual Compensation: $469.5K
Vice President and General Counsel
Age: 44
Total Annual Compensation: $383.8K
Chief Medical Officer and Senior Vice President
Age: 49
Total Annual Compensation: $377.2K
Chief Scientific Officer and Executive Vice President
Age: 62
Total Annual Compensation: $364.7K
Compensation as of Fiscal Year 2014.

OncoMed Pharmaceuticals, Inc. Key Developments

OncoMed Pharmaceuticals, Inc. Presents Updated Demcizumab Data in Non-Small Cell Lung Cancer at the 2015 ASCO Annual Meeting

At the 2015 ASCO Annual Meeting, OncoMed Pharmaceuticals Inc. presented data from a Phase 1b study open-label trial of demcizumab plus carboplatin and pemetrexed (Alimta) in patients with first-line advanced stage non-small cell lung cancer (NSCLC). Demcizumab is a first-in-class monoclonal antibody targeting DLL4 with anti-cancer stem cell, dysangiogenic and potential immune modulatory properties. Patients enrolled in the multi-center Phase 1b study either received six cycles of pemetrexed and carboplatin with demcizumab administered every three weeks on a continuous dosing schedule or four cycles of pemetrexed and carboplatin with truncated dosing of demcizumab followed by pemetrexed maintenance. Kaplan-Meier curves for the continuous dose cohort reveal prolonged progression-free survival and overall survival in a subset of demcizumab-treated patients. Of 23 patients in the continuous dosing cohort, ten (approximately 40%) survived more than two years. In these ten patients who survived more than 300 days, represented in the tail on the Kaplan-Meier survival curve, there was a cumulative 21.8 years of patient follow-up beyond those 300 days, and among these ten patients, only two patient deaths occurred as of the February 26, 2015 data cut off. Survival data from patients treated with the truncated demcizumab dose regimen is less mature, although the Kaplan-Meier curve shows a similar trajectory as of the February 2015 cut-off date. A retrospective analysis of patient tumor samples was conducted looking at a number of biomarkers related to demcizumab's mechanism of action, including tumor expression of the DLL4 protein, tumor expression of the programmed death receptor ligand-1 (PD-L1), and presence of immune cells within tumors, in order to identify potential predictive biomarkers for the apparent prolonged survival of certain patients treated with demcizumab. A total of 46 patients were enrolled in the Phase 1b study, with 40 evaluable for efficacy across both cohorts. One patient (3%) had a complete response, 19 (48%) had partial responses and 15 (38%) had stable disease as measured by RECIST criteria. The overall clinical benefit rate was 88%.

OncoMed Pharmaceuticals, Inc. - Special Call

To discuss clinical-stage company developing novel therapeutics that target cancer stem cell

OncoMed Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 08:00 AM

OncoMed Pharmaceuticals, Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-02-2015 08:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Paul J. Hastings, Chairman, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
Provasculon, Inc. United States
Oxford Biomedical Research Inc. United States
Kenna Technologies, Inc. United States
Counterpoint Health Solutions, Inc. United States
Nutraceutical Research Innovations LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OncoMed Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at